Mitochondrial phosphoenolpyruvate carboxykinase (PCK2) is a rate-limiting enzyme that plays critical roles in multiple physiological processes. The decompensation of PCK2 leads to various energy metabolic disorders. However, little is known regarding the effects of PCK2 on osteogenesis by human mesenchymal stem cells (hMSCs). Here, we report a novel function of PCK2 as a positive regulator of MSCs osteogenic differentiation. In addition to its well-known role in anabolism, we demonstrate that PCK2 regulates autophagy. PCK2 deficiency significantly suppressed autophagy, leading to the impairment of osteogenic capacity of MSCs. On the other hand, autophagy was promoted by PCK2 overexpression; this was accompanied by increased osteogenic differentiation of MSCs. Moreover, PCK2 regulated osteogenic differentiation of MSCs via AMP-activated protein kinase (AMPK)/unc-51 like autophagy activating kinase 1(ULK1)dependent autophagy. Collectively, our present study unveiled a novel role for PCK2 in integrating autophagy and bone formation, providing a potential target for stem cell-based bone tissue engineering that may lead to improved therapies for metabolic bone diseases. STEM CELLS 2019;37:1542-1555 
INTRODUCTION
Due to the ease of their accessibility and their multipotent properties, mesenchymal stem cells (MSCs) have emerged as promising candidates for use in bone tissue engineering to repair bone defects [1] . Exploration of mechanisms underlying differentiation of MSCs toward osteogenic lineages may facilitate improved clinical application of MSCs in the treatment of metabolic bone diseases, which confers significant burden for patients and the healthcare system.
During the process of forming new bone matrix and mineral deposition, MSCs can encounter deficiencies in energy supply, and may have difficulty meeting the increased metabolic demand associated with self-renewal and osteogenic differentiation [2] . Under these conditions, anabolism in MSCs is elevated to ensure a sufficient energy supply, including reduced glycolysis and increased mitochondrial respiration [3] . With the increase of anabolism, useless organelles and metabolites accumulate in cells. To maintain homeostasis in MSCs, the amount of cellular proteins and organelles should be strictly restricted. Autophagy is a degradative mechanism by which cells remove damaged and dysfunctional components to recycle macromolecules and provide energy under the stress of differentiation [4] . Amino acids from organelles degraded by autophagy can be used as an optional nutrient supply for cell survival [5] , making autophagy a suitable energy-refueling process during osteogenesis by MSCs. Previous studies have found the levels of autophagosomes present in MSCs [6, 7] is higher than that of many differentiated cells. The autophagic flux was observed in early MSC osteogenesis, suggesting that autophagy is critical in MSC differentiation [7] . Activation of autophagy was reported to significantly increase osteogenic differentiation and could rescue bone volume (BV) [8] . Impaired autophagy was also found in the wellknown skeletal degenerative diseases-osteoporosis [9] . These studies suggest that autophagy, as a vital link in the chain of energy metabolism, has a profound impact on the osteogenesis by MSCs. However, the regular mechanisms between autophagy and osteogenesis by MSCs have not been elaborately demonstrated.
Under conditions of nutrient-deprivation environment, gluconeogenesis is the primary source for endogenous glucose production [10] . Phosphoenolpyruvate carboxykinase (PEPCK) is an important enzyme in gluconeogenesis that catalyzes the decarboxylation of oxaloacetate (OAA) to phosphoenolpyruvate (PEP) in the tricarboxylic acid (TCA) cycle. Subsequently, through the activity of various enzymes in the glycolytic pathway, PEP can be transformed to glucose [11] . There are two isoforms of PEPCK: a cytosolic isoform (PEPCK1 or phosphoenolpyruvate carboxykinase [PCK1]) and a mitochondrial isoform (PEPCK2 or PCK2). Although the physiological function and regulatory patterns of PCK1 have been extensively explored [12, 13] , the biological role of PCK2 is poorly understood. It has been reported that the stability of PCK1 [14] is regulated by acylation, and that hyperacetylated PCK1 can promote anaplerotic activity [15] . Additionally, PCK1 promotes the ability of cells to uptake glucose and glutamine by increasing the metabolism of fatty acids and nucleic acids [12] . Nevertheless, a mitochondrial mtGTP/ PCK2 signaling may regulate glucose homeostasis by modulating the production and clearance of glucose, which suggests a role for PCK2 as a "metabolic tachometer" to sense TCA cycle flux [16] . Under low-glucose conditions, PCK2 allows cells to produce PEP from glutamine, which is used as a biosynthetic intermediate [17] . Therefore, the essential function of PCK2 in regulating gluconeogenesis is required for cells in a nutrient-deficient environment [18] . In light of the increasing energy demands during osteogenic differentiation, we wondered if PCK2 modulates osteogenic differentiation by influencing the cellular metabolic network.
The decompensation of PCK2 could lead to a series of energy metabolic disorders, such as diabetes mellitus [19] and glucose intolerance [20] , which will further lead to bone metabolic diseases. Exploration of the role of PCK2 in regulating osteogenesis is central to the understanding of the pathogenesis and treatment of skeletal diseases such as osteoporosis. In the current study, we discovered that PCK2 is a positive regulator of osteogenesis by MSCs and serves an indispensable role in autophagy. Mechanistically, PCK2 promotes the osteogenic capacity of MSCs through AMP-activated protein kinase (AMPK)/unc-51 like autophagy activating kinase 1 (ULK1)-mediated autophagy. This study was the first to emphasize the vital role of PCK2 in promoting the osteogenic capacity of MSCs by regulating autophagy, which may lead to the establishment of new strategies for bone tissue engineering. Moreover, therapeutic intervention by targeting PCK2 in certain types of metabolic disorders might be beneficial.
MATERIALS AND METHODS

Cell Culture
The human adipose-derived stem cells (hASCs) and human bone marrow mesenchymal stem cells (hBMSCs) used in our study were obtained from ScienCell Research Laboratory (Carlsbad, CA). Cells in this study were between three and five passages and obtained from three healthy adult donors. All materials used in cell culture were bought from Sigma-Aldrich (St. Louis, MO). For the in vitro experiments, proliferation medium (PM) for hASCs consisted of fetal bovine serum (FBS; 10%, vol/vol), penicillin G (100 U/ml), and streptomycin (100 mg ml) into Dulbecco's modified Eagle's medium; the PM for hBMSCs consisted of Minimum Essential Medium α (α-MEM, Gibco, Grand island, USA), 10% (vol/vol) FBS, penicillin G (100 U/ml), and streptomycin (100 mg/ml). Dexamethasone (100 nM), L-ascorbic acid (200 mM), and β-glycerophosphate (10 mM) were added into PM to make osteogenic medium (OM). The cell culture conditions were 95% air, 5% CO 2 , 100% relative humidity, and 37 C.
Lentiviral Transfection
Lentiviral transfection was performed as previously described [21] . Lentiviruses targeting PCK2 (sh1-PCK2, sh2-PCK2) and negative control (NC) vectors (NC1/NC2) were purchased from GenePharma Co. (Suzhou, China). Lentiviruses targeting ATG7 (sh1-ATG7, sh2-ATG7), NC, and lentiviruses containing PCK2 and the scramble control (vector) were purchased from Vector Builder Co. (Guangzhou, China). Multiplicity of infection of 100 was found to be suitable for transfection. When cells were exposed to the viral suspension, 5 mg/ml polybrene (Sigma) was added. After 72-96 hours, cells were incubated with puromycin (1 μg/ml, Sigma-Aldrich). The shRNA sequences used for PCK2 and ATG7 knockdown are shown in Table 1 .
RNA Interference and Plasmid Transfection
The sequences of short interfering (si) RNAs targeting ULK1 (si1-ULK1, si2-ULK1) and the negative control (si-NC) are listed in Table 1 and were purchased from GenePharma Co. The si-RNA targeting AMP-activated protein kinase (si-AMPK) was obtained from HanBio (Shanghai, China). The pCIP-AMPKα1_WT plasmid was a gift from Reuben Shaw (Addgene plasmid # 79010; http://n2t.net/addgene:79010; RRID: Addgene_79010). The wild-type PCK2 (pEnCMV-PCK2-3 × FLAG) and mutant PCK2 plasmids (pEnCMV-PCK2-K261.262R-3 × FLAG) were constructed. Based on the manufacturer instructions, Lipofectamine 3000 (Invitrogen, Carlsbad, USA) was used as a transfection agent. After 48 hours, cells were collected and gene expressions were analyzed. During the process of osteogenesis, transfection was repeated every 5 days to ensure transfection efficiency and hASCs were harvested at 7 and 14 days after osteogenic induction.
Cell Proliferation Assay
Cells were seeded in 96-well plates at a density of $2 × 10 3 cells per well. At days 1-8, cells were incubated with 20 μl cell counting kit-8 (CCK-8) assay kit to analyze cell proliferation (Dojindo Laboratories, Kumamoto, Japan). After 1.5 hours at 37 C, the absorbance at 490 nm was measured for each well, and cell proliferation curves were plotted. The experiments were repeated at least three times. Each group was tested in three replicate wells. and activity were conducted according to previously established protocols [22] . The 5-bromo-4-chloro-3-indolyl-phosphate/ Nitro-Blue-Tetrazolium staining kit (CoWin Biosciences, Beijing, China), bicinchoninic acid (BCA) protein assay kit (Prod#23225, Pierce Thermo Scientific, Waltham, MA) and ALP assay kit (A059-2, Nanjing Jiancheng Bioengineering Institute, Nanjing, China) were used.
Alizarin Red S Staining and Quantification
For alizarin red S (ARS) staining and quantification, hASCs were seeded in six-well plates. On the 14th day of osteoinduction, cells were fixed with 95% ethanol for 30 minutes at room temperature. After washed with distilled water for three times, the cells were incubated with ARS solution (2%, pH 4.2, Sigma-Aldrich). For quantification, the plate was incubated with 100 mM cetylpyridinium chloride (Sigma-Aldrich) for 1 hour and the solution was collected. According to previously established protocols [23, 24] , the absorbance of solution was measured at 562 nm and normalized to the total protein concentration.
RNA Collection and Quantitative Reverse Transcription Polymerase Chain Reaction
Cells (hASCs and hBMSCs) were seeded in six-well plates, and total cellular RNA was extracted after 7 and 14 days of osteoinduction. Quantitative real-time PCR was conducted as described previously [25] . The expression of glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was detected for normalization of gene expression. The primers used for PCK2, PCK1, GAPDH, ATG7, RUNX2, ALP, OCN, LC3B, p62, and ULK1 are listed in Table 1 . To analyze the fold differences in relative expression, the cycle threshold values (Ct values) were calculated using the 2 −ΔΔCt method.
Immunofluorescence Staining
The hASCs were seeded on confocal plates cultured in PM and OM, separately. After 7 days, cells were fixed in 4% paraformaldehyde and treated as previously described [26] . The antibody (1:200 dilution) against the autophagy marker LC3B was from Cell Signaling Technology (Danvers, MA) and goat antirabbit fluoresceine isothiocyanate (green, 1:150 dilution) was from Gibco. DAPI (blue) was used for staining nuclei. Fluorescence staining was visualized using a Confocal Zeiss Axiovert 650 microscope with the appropriate excitation wavelengths.
Western Blot Analysis
The total protein of hASCs or hBMSCs were prepared in radioimmunoprecipitation assay buffer including protease inhibitor mixture (Roche Applied Science, Mannheim, Germany) and phosphatase inhibitors (Keygenbio China, kgp602). Then the lysates were harvested and centrifuged at 14,000 rpm at 4 C for 15 minutes. The protein concentration was measured by using Pierce BCA protein assay kit (Thermo Scientific). Equal amount of the protein extracts was separated on proper SDS-PAGE (7.5%, 10%, or 15%) and transferred to polyvinylidene difluoride membrane (Bio-Rad). After blocking in 5% milk for Table 1 . Sequences of RNA and DNA oligonucleotides Name Sense strand/sense primer (5 0 -3 0 ) Antisense strand/antisense primer 
Heterotypic Bone Formation Assay in Vivo
The hASCs stably infected with NC, sh1-PCK2, sh2-PCK2, PCK2, and vector, PCK2 + sh1-ATG7, PCK2 + si-ULK1 were mixed with beta-tricalcium phosphate (β-TCP; Bicon, Boston, MA) particles. The complexes were implanted subcutaneously under the dorsal space of 42-day-old, BALB/c homozygous nude (nu/nu) mice (n = 10 mice per group, each experiment was performed three times). The specific procedure for nude mouse implantation has been previously described [22] [23] [24] . The Institutional Animal Care and Use Committee of the Peking University Health Science Center approved the performance of this study (LA2014233) and all in vivo experiments were conducted in accordance with Institutional Animal Guidelines.
Micro-Computed Tomography Analysis of Xenograft Mice
To assess the mass and shape of the new bone among each group, the specimens were scanned with an Inveon MM system (Siemens, Munich, Germany) after fixation as previously described [27] . The scanning conditions were an X-ray voltage of 80 kV, current of 500 μA, and exposure time of 1,500 ms for each of the 360 rotational steps. For quantification of the images, BV/total volume (TV) [28] was calculated using an Inveon Research Workplace (Siemens). Image-Pro Plus software (Media Cybernetics, Rockville, MD) was used to measure the percentage of new bone or collagen formation area [(bone or collagen area/total tissue area) * 100%]. Quantitative results were exhibited by histograms.
OAA Concentration Measurement
The hASCs transfected with pcDNA3.1, wild-type, and mutant PCK2 were incubated with 4 μg OAA (Macklin, 328-42-7) for 1 hour and the cells were rapidly homogenized with OAA assay buffer. The remnant OAA concentration was measured according to the protocol of OAA assay kit (Sigma, MAK070). The concentrations of OAA were calculated by building the calibration curve for 0-1 nmole per well standards.
Analyses of Bone Formation In Vivo
Samples were collected after 8 weeks and fixed in 4% paraformaldehyde for 24 hours. Samples were decalcified for 14 days using 10% ethylene diamine tetra acetic acid (EDTA; pH 7.4). Samples were then dehydrated and embedded in paraffin. Next, sections were cut into 5-6 μm thick slices and stained with hematoxylin and eosin (H&E) and Masson's trichome. An inverted fluorescent microscope (Olympus Co., Tokyo, Japan) was used for visualization and analysis of tissue slices.
Statistical Analysis
SPSS Statistics 20.0 software (IBM, Armonk, NY) was used for statistical analysis. The results are presented as a summary of the mean of three independent experiments and data were indicated as mean AE SD. For comparisons between two experimental groups, Student's t test was used. A two-tailed p-value ≤.05 was considered to indicate statistical significance.
RESULTS
PCK2 Promotes Osteogenic Differentiation of MSCs
To explore PCK2 impact upon MSCs as they differentiate toward osteogenic lineages, stable hASCs and hBMSCs cell lines transfected with lentivirus for PCK2 knockdown or overexpression were constructed. Two shRNA sequences targeting PCK2 were used to avoid off-target effects. The lentiviral transduction efficiency of hASCs was confirmed by fluorescent staining (Supporting Information Fig. S1A Fig. S2G, S2H ). In addition, overexpression of PCK2 enhanced ALP activity ( Fig. 2A, 2B ). Overexpressing PCK2 resulted in an increase in the relative mRNA expression levels of RUNX2 and ALP after 7 days of osteogenic differentiation (Fig. 2C, 2D ). In addition, PCK2 overexpressing cells demonstrated more extracellular matrix mineralization ( Fig. 2E, 2F ) and elevated gene expression of osteogenic markers after 14 days of osteogenic induction (Fig. 2G, 2H ). Moreover, compared with control cells, the protein level of RUNX2 was upregulated in PCK2 overexpressing cells ( Fig. 2I ) and was downregulated in PCK2 deficient cells ( Fig. 2L ; Supporting Information Fig. S2I ).
In confirmation of the PCK2-regulated osteogenic differentiation of hASCs as a general phenomenon, we constructed stable cell lines of hBMSCs transfected lentivirus for PCK2 knockdown and overexpression. The transfection efficiency was confirmed (Supporting Information Fig. S1G -S1I). The observations suggested similar results when hBMSCs were treated under the same conditions (Supporting Information Fig. S2J-S2Q ). Furthermore, as a critical enzyme for glucose anabolism, PCK2 catalyzes OAA to PEP. To assess whether PCK2-mediated osteogenic differentiation is associated with enzymatic activity of PCK2, pcDNA3. Fig. S2R ). The mutant PCK2 transfection decreased ALP activity during osteogenic differentiation, compared with wild-type PCK2 group (Supporting Information Fig. S2S, S2T ). Collectively, these data demonstrate that PCK2 is a positive regulator of the osteogenic capacity of MSCs in vitro.
PCK2 Enhances Ectopic Bone Formation from hASCs In Vivo
The in vitro results suggest that PCK2 exerts a vital regulatory effect on osteogenesis by hASCs and we next explored whether PCK2 plays an important role in bone formation in vivo. The hASCs expressing PCK2, sh1-PCK2, and sh2-PCK2 were mixed with β/TCP, separately, and the complexes were implanted into nude mice (n = 10 for each group). The samples were harvested at 8 weeks. According to representative images of H&E staining, hASCs/sh1-PCK2 cells and hASCs/sh2-PCK2 cells formed much less osteoid tissues, with some scaffold remnants, compared with control cells (Fig. 3A) . Simultaneously, lower amounts of organized extracellular matrix with collagen fiber accumulated in PCK2 knockdown groups (blue color as indicated by Masson's trichrome staining; Fig. 3B ). Histomorphometry analysis of bone-like tissues illustrated that the area of bone formation was markedly decreased in PCK2 knockdown groups compared with the control group (Fig. 3A, B) . Consistently, micro-CT analysis also suggested that PCK2 knockdown groups exhibited less new bone formation and more scaffold remnants (Fig. 3C ). Quantifications of micro-CT images further displayed that the percentage of BV to TV in the PCK2 knockdown groups was less than the control group. In contrast, overexpression of PCK2 resulted in much more uniform, acidophilic osteoid tissue as shown by H&E staining, compared with the control vector group, including some microvascular formation (Fig. 3D ). Meanwhile, more organized extracellular matrix with collagen fiber accumulation (Fig. 3E ) was shown in PCK2-expressing group. Consistently, micro-CT and quantitative measurement also demonstrated that the percentage of BV to TV in the PCK2 overexpression group was more than the control group (Fig. 3F) . These results displayed similar outcomes to the in vitro findings ( Figs. 1 and 2 ; Supporting Information Figs. S1 and S2) and further confirmed that PCK2 enhances the osteogenic differentiation, thereby promoting ectopic bone formation in vivo (Fig. 3 ).
PCK2 Modulates Autophagy During Osteogenic Differentiation
Our results indicated that PCK2 plays a significant role in promoting osteogenic differentiation of MSCs, but the regulatory mechanism involved in this process remained unclear. Because autophagy is an important process in protecting stem cells from metabolic stress [29] , we next examined whether PCK2 is involved in regulating autophagy of MSCs. Microtubule associated protein 1 light chain 3 β (LC3B) accumulation and p62/SQSTM1 (p62) degradation were used as two biological markers of autophagy [30] , and were evaluated by immunoblotting. Treatment with H 2 O 2 (500 μM)-induced p62 Fig. S3A ). However, the increase in LC3B not only demonstrates increased autophagy flux, but also indicates the inhibition of autophagosome degradation [31] . To measure the autophagy flux precisely, protease inhibitors E64d (10 μg/ml) and pepstatin A (pep, 10 μg/ml) were used to suppress the fusion of autophagosomes with the lysosome, resulting in the accumulation of LC3B and the blockade of p62 degradation. H 2 O 2 treatment significantly increased autophagy flux in control cells, but not in PCK2 knockdown cells (Fig. 4B; Supporting Information Fig. S3F ), further suggesting that depletion of PCK2 markedly suppresses autophagy. Meanwhile, compared with the control group, overexpression of PCK2 promoted the accumulation of LC3B and the degradation of p62 ( Fig. 4C; Supporting Information Fig. S3D ). To confirm the positive regulatory effect of PCK2 on autophagy, we assessed autophagy flux in cells cultured under conditions of serum starvation with or without pep + E64d. As expected, we observed a (Fig. 4D-4F ; Supporting Information Fig. S3B, S3E ) . Altogether, these results demonstrate that PCK2 plays an important role in enhancing autophagy of MSCs. To investigate whether PCK2 exerts a regulatory influence on autophagy during osteogenic differentiation, we examined the autophagy flux of hASCs after 7 days of osteogenic induction. The increasing level of RUNX2 protein determined the osteogenic differentiation of hASCs ( Fig. 4G and Supporting Information Fig. S3C) . In contrast to the control cells, a dramatic decrease of LC3B and reduced p62 degradation were observed in PCK2 knockdown cells cultured in OM. Concurrently, after 7 days of osteogenic induction, overexpression of PCK2 increased autophagy compared with the control vector group, as demonstrated by increased aggregation of LC3B and degradation of p62 (Fig. 4H) . These results demonstrate that PCK2 positively regulates autophagy during osteogenesis by MSCs.
To further evaluate the dynamic variation of autophagy flux during osteogenesis by MSCs, LC3B turnover was measured after pep + E64d treatment. During osteogenic differentiation of hASCs, knockdown of PCK2 significantly reduced autophagy flux (Fig. 4I ). The similar trend was observed during osteogenic differentiation of hBMSCs (Supporting Information Fig. S3H ). In addition, autophagosomes were observed by fluorescence microscopy, indicated by a marked increase in LC3B puncta after osteogenic induction (Fig. 4J ). Based on these data, it can be inferred that PCK2 regulates osteogenic differentiation of MSCs through modulating autophagy.
Autophagy Is Indispensable for Osteogenic Differentiation
We investigated the specific role of autophagy as a regulator of osteogenesis by hASCs. ALP activity and ARS staining/quantification were used to confirm the osteogenic capacity of hASCs (Supporting Information Fig. S4A-S4C ). Western blot analysis showed that LC3B accumulates during osteogenic differentiation, accompanied by degradation of p62 (Supporting Information Fig. S5A, S5B ). Gene expressions determined by qRT-PCR corroborated these findings (Supporting Information Fig. S4D-S4F ). These data suggest that autophagy is involved in hASCs osteogenic differentiation.
Autophagy is a multistep process and can be suppressed at different stages [32] . To examine the regulatory effect of autophagy on osteogenic capacity, we used two classic inhibitors of autophagy: 3-methyladenine (3-MA, 5 mM), which suppresses phosphoinositide 3-kinases (PI3Ks), and chloroquine (10 μM), which impairs the fusion of the autophagosome to the lysosome. Both inhibitors blocked osteogenesis by hASCs as demonstrated by a decrease in ALP activity (Supporting Information Fig. S4G-S4J ) and reduced expression of RUNX2 mRNA (Supporting Information Fig. S4K-S4L) .
To further substantiate the regulatory effects of autophagy on osteogenesis, two lentiviral sequences encoding sh-ATG7 and the scrambled control shRNA (NC) were transfected into hASCs. Transduction efficiency was confirmed by immunofluorescence, qRT-PCR (Supporting Information Fig. S5C, S5D) , and Western blot (Supporting Information Fig. S5E ). After 7 days of osteogenic induction, depletion of ATG7 downregulated ALP activity (Fig. 5A, 5B) . Moreover, the extracellular matrix mineralization and quantification were also decreased in ATG7 depleted cells after 14 days of osteogenic induction (Fig. 5C, 5D ). Furthermore, qRT-PCR results demonstrated a corresponding reduction in the relative mRNA level of osteogenic-related marker genes at the 7th (Supporting Information Fig. S5F, S5G ) and 14th days (Fig. 5H, 5I ) of osteogenic differentiation. During the course of osteogenic differentiation, knockdown of ATG7 led to significant impairment of autophagy flux and inhibited osteogenic differentiation of hASCs (Fig. 5E ), as indicated by decreased RUNX2 protein expression. Altogether, these data show that activation of autophagy is necessary for the osteogenesis by hASCs.
PCK2 Promotes Osteogenic Differentiation by Regulating AMPK/ULK1-Mediated Autophagy
To precisely assess the regulatory effects of PCK2 on osteogenic differentiation through autophagy, 3-MA, which inhibits autophagy activity, was used to treat PCK2-expressing cells. Compared with PCK2-overexpressing cells, the mRNA expression of osteoblastic markers was attenuated in PCK2 + 3-MA cells during osteogenic induction (Supporting Information Fig. S5F-S5I) . Similarly, treatment of cells with 5 mM 3-MA inhibited ALP activity (Fig. 5J, 5K ) and reduced ARS staining/quantification (Fig. 5L, 5M) , which were enhanced by PCK2 overexpression. Most importantly, upon 3-MA treatment, overexpression of PCK2 failed to elevate osteogenesis in hASCs, as shown by the significant reduction of RUNX2 protein (Fig. 5N) . These results prove that PCK2 facilitates osteogenic differentiation of hASCs by regulating autophagy.
As a key initiator of lysosomal-dependent autophagy, unc-51 like autophagy activating kinase 1 (ULK1) serves important roles in cellular nutrient degradation during processes such as glucose metabolism and lipid metabolism [26, 33] . To further explore the molecular mechanism by which PCK2 regulates autophagy during osteogenic differentiation, we performed Western blot analysis to score changes of ULK activity in PCK2 knockdown cells. We found a dramatic increase in ULK1 phosphorylation during osteogenic differentiation, particularly at serine 555 (Ser 555), serine 556 (Ser 556), and serine 757 (Ser 757; Fig. 6A ; Supporting Information Fig. S6A ). However, knockdown of PCK2 significantly attenuated phosphorylation of ULK1 ( Fig. 6A ; Supporting Information Fig. S6A ). Meanwhile, overexpression of PCK2 led to upregulation of ULK1 phosphorylation at Ser 555, Ser 556, and Ser 757 during osteogenesis (Fig. 6B ). AMPK integrates various metabolic signals and can activate ULK1 through phosphorylation at multiple sites [34] [35] [36] . Our results indicate that the pattern of AMPK phosphorylation corresponds with ULK1 expression after knockdown or overexpression of PCK2 ( Fig. 6A, 6B ; Supporting Information Fig. S6A ). To examine the potential role of ULK1 during the osteogenesis by hASCs, two si-RNA sequences were used to suppress ULK1 expression, and the knockdown efficiency was confirmed by the qRT-PCR (Fig. 6C) . Analysis of the mRNA expression of RUNX2 (Fig. 6D ), ALP activity (Fig. 6E, 6F) , and ARS staining/ quantification (Fig. 6G, 6H ) showed that depletion of ULK1 significantly inhibits osteogenic differentiation of hASCs. These data demonstrate that ULK1 is a positive regulator of osteogenic differentiation. To further explore the regulatory effect of PCK2 on autophagy and osteogenic differentiation through AMPK/ULK1 signaling pathway, si-AMPK was added in the PCK2-expressing cells and wild-type-AMPK plasmid was transfected in the PCK2-knockdown cells. The transfection efficiency was confirmed by Western blot (Supporting Information Fig. S6B ). The results displayed that elevated osteogenic capacity and autophagy activity of PCK2-overexpression cells was significantly suppressed by the inhibition of AMPK (Fig. 6I) , whereas the decreased osteogenic ability and autophagy activity induced by PCK2 inhibition was rescued by overexpression of AMPK (Fig. 6J ). To verify our in vitro findings, we next investigated the potential role of AMPK/ULK1 on osteogenic differentiation in vivo. H&E staining, Masson's trichrome staining from implanted hASC-scaffold hybrids demonstrated that inhibiting ATG7 or suppressing ULK1 expression in PCK2-expressing cells led to significant suppression of osteogenic differentiation (Fig. 6K-6N ). Altogether, these findings suggest that PCK2 regulates osteogenic differentiation through AMPK/ULK1-mediated autophagy.
DISCUSSION
The important effects that PCK2 exerts in regulating gluconeogenesis and the TCA cycle ideally fulfill the energy requirements of MSCs osteogenic differentiation, and prompted us to examine the roles of PCK2 in the osteogenic capacity of MSCs. The increasing energy demands on MSCs during osteogenic differentiation not only require increased anabolism, but also require a strict regulation of protein turnover and lysosome-mediated degradation of cellular substances [37] . Autophagy is a catabolic process that efficiently degrades damaged organelles and macromolecules in the lysosome, allowing the nutrients to be recycled under conditions where there the external energy supply is limited [38] . In our current study, we discovered that PCK2 acts as a potent regulator promoting the osteogenic capacity of MSCs, and we unveiled a previously unreported function of PCK2. Our findings extend the knowledge about the molecular mechanisms of PCK2 as a positive factor in the osteogenic differentiation of MSCs. Interestingly, through exploring potential mechanisms, we observed a positive regulatory effect of PCK2 on autophagy during osteogenesis by MSCs. A recent study demonstrated that depletion of autophagy-related-genes, such as ATG5 and BECN, leads to impaired osteogenic ability of BMSCs in vivo [9] . In accordance with this study, we found that autophagy was indispensable for the osteogenesis by MSCs. More importantly, we demonstrated that PCK2 enhances the osteogenic differentiation through AMPK/ULK1-dependent autophagy. Taken together, our study identified PCK2 as a critical modulator that regulates autophagy and the osteogenic differentiation, demonstrating that PCK2 may be a potential therapeutic target for metabolic bone diseases.
PCK2 is responsible for approximately 50% of the total hepatic PEPCK functions in many mammals, including humans [39] [40] [41] . However, the specific biological roles of PCK2 are largely unknown. PCK2 has been reported to be critically involved in modulating glucose metabolism and lipid metabolism [41] . In addition, PCK2 regulates both insulin secretion and gluconeogenesis in order to ensure continuous cataplerotic PEP production [18] . The activity and expression of PCK2 were elevated under low-glucose conditions [42] . In general, PCK2 can be regarded as a key factor in energy metabolism by regulating glucose homeostasis and TCA cycle activity. We speculated that the metaphorical "metabolic tachometer" mechanism enables PCK2 to sense and coordinate appropriate responses to energy changes during the osteogenesis of MSCs. In order to explore the potential role of PCK2, we constructed stable PCK2 knockdown and overexpressing cells and determined the effects of modulating PCK2 expression on the osteogenic capacity of MSCs. Moreover, we observed that PCK2 is involved in positively regulating autophagy. PCK2-deficient cells demonstrated decreased autophagy flux whereas PCK2-overexpressing cells displayed significantly increased autophagy flux. The relationship between PCK2 and autophagy during osteogenesis by hASCs was further examined, and we found that depletion of PCK2 repressed autophagy, resulting in the impairment of the osteogenic ability of MSCs. On the contrary, when PCK2 was overexpressed, we found that autophagy was increased, accompanied by upregulation of osteogenic differentiation of MSCs. Incubation of autophagy inhibitors 3-MA significantly suppressed the osteogenic differentiation of PCK2-overexpression cells. Consistently, inhibition of ATG7 resulted in the decrease of osteogenic ability in PCK2-expressing cells in vivo, which verifies the idea that PCK2 regulates osteogenic ability of hASCs via modulating autophagy. Therefore, we provide the first demonstration that PCK2 exhibits a positive regulatory effect on osteogenic capacity of MSCs via modulating autophagy. In addition, our results offer a clue that PCK2, which is a critical enzyme for energy metabolism may constitute a new target for innovative therapeutic research in bone pathologies.
Emerging evidence has shown that autophagy is actively involved in the maintenance of bone homeostasis and regulation of skeletal metabolism [29, 43] . However, previous studies have mainly concentrated on terminally differentiated cells in the bone system, such as osteoblasts, osteocytes, and osteoclasts [44, 45] , and the potential regulatory role of autophagy in MSCs remains unclear [46] . It was reported that constitutive autophagy activity in human bone marrow-derived stem cells (hBMSCs) is upregulated in early stages of osteogenic induction [47] . The activation of autophagy promotes the osteogenic ability of hBMSCs from osteoporotic vertebrae [22] . Moreover, a recent study showed that diminished lineage differentiation could be partly rescued by activation of autophagy in osteoporotic BMSCs [9] . Investigations on the involvement of autophagy in hASCs have displayed similar results. A study reported that the suppression of autophagy led to the activation of the NF-E2-related factor 2 (Nrf2) pathway and the impairment of osteogenic ability of ASCs following stimulation with reactive oxygen species [21] . Consistent with this report, our study showed that the addition of the autophagy inhibitors 3-MA and CQ significantly suppressed the osteogenic capacity of hASCs (Supporting Information Fig. S4G-S4L ). We further confirmed the regulatory effects of autophagy on osteogenic differentiation of hASCs by depletion of ATG7. Knockdown of ATG7 inhibited bone formation, as demonstrated by mRNA (Supporting Information Fig. S5F -S5I) and protein ( Fig. 5E ) expression analysis of bone formation factors. Our results demonstrate that autophagy plays a positive role during the osteogenesis by hASCs.
A close interaction between autophagy and glucose metabolism has long been a focus of study, and the existence of a dynamic feedback between cellular energy balance and autophagy has been established [48, 49] . It has been reported that ULK1 acts as a dual integrator of energy metabolism and autophagy, by sustaining glucose metabolic fluxes through activation of autophagy, especially in conditions of nutritional-shortage [50] . AMPK is another important intracellular energy sensor, and activates autophagy by directly phosphorylating ULK1 [34] . Our data showed that both the phosphorylation of AMPK α subunit and phosphorylation ULK1 were regulated by PCK2 during osteogenic differentiation. In addition, inhibition of AMPK suppressed the osteogenic ability of PCK2-expressing cells, whereas transfection of wild-type AMPK rescued the decreased osteogenic capacity of PCK2-knockdown cells. Furthermore, suppressing of ULK1 expression impaired the osteogenic differentiation of PCK2-expressing cells in vivo. These results suggest that AMPK/ULK1-mediated autophagy is involved in the PCK2-regulated osteogenic differentiation. However, there are still some questions that remain to be explored. For example, while our study elucidated the regulatory function of PCK2 on autophagy and osteogenic differentiation of MSCs, the functional domain of PCK2 involved in this regulation remains unknown. In future studies, we aim to further evaluate the sites on the PCK2 protein, which are directly responsible for its regulatory functions.
CONCLUSION
In conclusion, our current study demonstrates a novel role of PCK2 in promoting bone formation of MSCs. Besides unraveling the function of PCK2 in osteogenic differentiation, our observations also contribute to the understanding of molecular mechanisms governing osteogenic capacity of MSCs. Mechanistically, PCK2 regulates osteogenic differentiation through regulating AMPK/ULK1-dependent autophagy. This newly discovered function for PCK2 could be exploited as a novel metabolic target for maintaining energy homeostasis and could facilitate the development of MSC-based clinical applications to treat bone metabolic diseases.
